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Summary Some oral cancers are preceded by premalignant lesions which include leucoplakia and erythrop-
lakia. At present there are no reliable markers to identify lesions that may progress to malignancy. We have
analysed 30 potentially malignant oral lesions for deletions at chromosomal regions that harbour tumour-
suppressor genes for oral cancer. A total of 16 of 30 cases (53%) showed loss of heterozygosity (LOH) or
allele imbalance at TP53, DCC, 3p2l.3-22.1 or 3pl2.1- 13. These genetic alterations were detected in
dysplastic lesions but not in histologically normal mucosa and may be early events in the carcinogenic process.
A total of 64% of dysplastic lesions that recurred during the study showed LOH or allele imbalance in the
initial biopsy and the number of genetic abnormalities increased in the tumours that developed. This type of
molecular profiling may help to identify patients with lesions that may recur or acquire additional genetic
events and progress to malignancy.
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Early treatment of oral cancer offers the best chance of cure.
However, patient awareness of this disease is low and as
most cases present late treatment is associated with
significant physical and psychological morbidity and reduced
survival. There is increasing awareness of the potential value
of screening for oral cancer and precancer to reduce mor-
bidity and mortality. The most significant oral precancers are
leucoplakia (a white patch) and erythroplakia (a red patch)
which may show varying degrees of dysplasia. Longitudinal
studies have shown that some of these lesions develop into
invasive squamous cell carcinoma (SCC), although others
regress. Depending on the population studied pre-existing
leucoplakia, the most common oral premalignant condition,
is associated with 16-32% of oral cancers (MacDonald,
1975). Erythroplakia is much rarer than leucoplakia but
shows a much higher risk of malignant transformation. The
clinical appearance of these lesions and recognised risk fac-
tors for oral cancer, which include heavy smoking and high
alcohol consumption, are poorly predictive for risk of
tumour development and therefore the lesions that will
ultimately become neoplastic cannot readily be identified.
At present most clinicians biopsy all suspicious red and
white patches treating only those showing severe dysplasia.
Management of lesions showing mild or moderate dysplasia
remains problematical as there are no markers that can
predict risk of progression to malignancy. It is generally
accepted that carcinogenesis involves the progressive accum-
ulation of genetic abnormalities (Fearon and Vogelstein,
1990). Epidemiological, molecular and statistical studies have
suggested that between six and ten genetic events are
required for head and neck cancers (Harris, 1991; Renan
1993). Genetic abnormalities affecting tumour-suppressor
genes including allele loss at 9p2l-22 (van der Reit et al.,
1994) and TP53 mutations (Boyle et al., 1993) have been
detected in preinvasive head and neck squamous cell car-
cinoma (SCC) and provide insight into early critical events.
Study of the number and nature of genetic abnormalities in
potentially malignant lesions may supplement existing his-
tological assessment and help predict the likely behaviour of
these oral lesions and identify patients who may benefit from
regular oral examination, preventative strategies and early
treatment when necessary.
We have screened potentially malignant oral lesions, with
evidence of dysplasia, for allele loss at TP53, DCC and for
regions at 3p, which harbour suppressor genes for oral
cancer. Normal mucosa was also examined to see whether
allelic deletion can precede histological changes. We detected
LOH or allele imbalance in the dysplastic lesions but not in
histologically normal mucosa, suggesting that this can be an
early event in the carcinogenic process. The frequency of
these genetic abnormalities was higher in the tumours that
developed. This suggests that specific deletions at TP53, DCC
and 3p in potentially malignant lesions may identify lesions
that acquire additional genetic alterations and progress to
cancer.
Materials and methods
To obtain dysplastic tissue we biopsied areas of leucoplakia
and erythroplakia that were surgically excised, occurring in
the absence of frank carcinoma (17 cases). We also biopsied
areas adjacent to frank SCC (11 cases). Two other samples
were new dysplastic lesions developing following treatment of
a primary SCC. All cases were followed for a minimum
period of 36 months. Eleven patients developed a further
suspicious lesion, with evidence of dysplasia at the same site
or close to the original biopsy. Two patients subsequently
developed SCC within 18 months (see Table I).
The majority of each sample was snap frozen in liquid
nitrogen and stored at - 70°C. A portion of each biopsy was
fixed in formalin and processed for routine histopathological
examination. The degree of dysplasia ranged from mild (12
cases), moderate (ten) to severe (eight). Venous blood was
stored in sodium chloride EDTA tubes and kept at - 20°C
until required. In some cases histologically normal mucosa,
from the margin of a biopsy (cases 1-11) or obtained from
the opposite side of the mouth (cases 12-30), was available
as a further control.
Frozen sections (10f) were mounted onto microscope
slides with double-sided sticky tape and stained with
toluidine blue. The normal epithelium, dysplastic epithelium
and tumour were microdissected from the slide and digested
in 50til of lysis buffer (50 mM TRIS pH 8.3, 1 mM EDTA,
0.5% Tween 20, 500 ,tg ml-' proteinase K (Wright and
Manos, 1990). After incubation at 55°C overnight the pro-
tease was inactivated by 10 min at 95°C. Polymerase chain
reaction (PCR) was performed directly on these aliquots.
Genomic DNA was extracted from venous blood by lysis
with Triton-X100.
To examine LOH at D3S686, D3S32 and D3S30 PCR-
restriction fragment length polymorphism (RFLP) analysis of
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Table I Clinicopathological features
Case l
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Age
50
65
55
68
55
60
52
69
45
64
68
45
63
35
30
32
73
42
46
74
78
58
80
52
53
48
78
50
54
56
Site
FOM
Lateral tongue
Buccal
Lateral tongue
Commissure
FOM
Alveolus
Lateral tongue
FOM
Buccal
Buccal
FOM
FOM
Lateral tongue
Buccal
Buccal
FOM
Buccal
Ventral tongue
Dorsum tongue
FOM
FOM
Alveolus
FOM
FOM
Buccal
Buccal
FOM
FOM
Alveolus
and risk factors for potentially malignant oral
lesions
Tobacco
60
NIL
NA
NIL
20
20-40
10
10-15
10-15
NIL
15
20
6
20-30
20
20
20
Betel
NIL
15
NIL
100
40
20
25
Betel
NIL
30
NIL
15
Habits
Alcohol
1-4
NIL
NA
Incidental
NA
4-8
NA
NA
NA
Incidental
NA
4-8
Incidental
Incidental
Incidental
Incidental
1-4
NIL
NA
Incidental
NIL
4-8
NIL
NIL
8-16
NIL
8-16
8-16
Incidental
4-8
Degree of
dysplasia
Milda
Milda
Mild
Severea
Mild
Severea
Milda
Moderate
Mild
Severe
Moderate
Severe
Moderateab
Moderate
Milda
Milda
Severea,b
Moderate
Severe
Mild
Moderate
Moderate
Moderatea
Moderate
Moderate
Mild
Mild
Severea
Severe
Mild
Cases 1-17, dysplastic lesions from patients without SCC; cases 18-19 new lesions
developing after SCC; 20-30 dysplastic lesions adjacent to invasive SCC. FOM, floor of
mouth. Tobacco usage isgiven as numberofcigarettes smoked perday, alcohol consumption
is the number ofunits perday. aNew dysplastic lesion after surgical excision. bSCCdeveloped
during the period of study.
normal and dysplastic samples was performed using two
rounds of PCR analysis as previously described (Sundaresan
et al., 1992). Amplification was performed in a volume of
50pl containing 5 ,sl of DNA solution or 500 ng of genomic
DNA. An aliquot of 15 jsl of the product was digested with
10 units of the appropriate restriction enzyme. The digests
were fractionated on 4% agarose gels, stained with ethidium
bromide and photographed. Allele (i) is the undigested
amplification product, allele (ii) is composed of digested
fragments.
PCR primers for 14 polymorphic microsatellite markers
(see Table I) were obtained from Research Genetics, Huntsvi-
lle, USA or synthesised locally. One of the primers was
end-labelled with [y-32P]ATP and PCR products generated
from standard reactions. Products were separated by gel
electrophoresis in denaturing 8% polyacrylamide-8M urea
and autoradiographed overnight. Labelled M13mp8 was
included as a sequencing ladder to facailitate sizing of the
alleles. The map positions of the markers (see Table II) are
given as indicated by the sigma mapping programme using
data from the Genome Data Base, The Johns Hopkins
University (Naylor et al., 1994).
Allele loss was scored if the signal of one of the alleles was
reduced by approximately 50% when DNA from dysplastic
lesions or tumour was compared with normal DNA. PCR-
based techniques may not distinguish between allele loss or
gain and alteration of allele intensities is often designated
allele imbalance rather than LOH. However when using
equivalent amounts of DNA, we rarely detected
overamplification of one allele with loss, or reduction in
intensity of the other allele when comparing dysplastic lesions
with normal samples. Loci showing reduced intensity of one
allele were generally confined within regions considered to
harbour tumour-suppressor genes. Taken together these
findings suggest that allele imbalance detected in this study is
likely to be due to LOH rather than amplification of large
chromosomal regions.
Results
Table I lists the cases analysed and includes relevant clinical
information. The results are presented for dysplastic lesions
occurring in the absence of SCC and for lesions with an
invasive component, either concomitant or in a previous
biopsy. Three of 16 (18%) patients informative at TP53 and
1 of 11 (9%) cases informative at DCC showed LOH or
allele imbalance when the dysplastic epithelium was com-
pared with normal oral mucosa and blood. The frequency of
LOH or allele imbalance was increased when dysplastic
lesions with an invasive component were considered with two
of ten (20%) cases showing LOH at TP53 and four of nine
cases (44%) showing LOH at DCC (Table II). The frequency
of LOH or allele imbalance also varied for each locus at 3p,
ranging from 1-12% of dysplastic lesions without SCC to
0-19% of cases with an invasive component. When alleles
were lost in the dysplasia, loss was not always complete
probably as a result of contamination of the lesion with
normal cells. However, we cannot exclude the possibility of
some genetic variation within the samples (Nowell et al.,
1976).
A deletion map of chromosome regions where partial loss
of loci at 3p and LOH at TP53 and DCC was detected is
shown (Figure 1) with representative cases (Figure 2). Allelic
deletions or imbalance generally involved single loci,
although some samples showed deletion with adjacent pro-
bes. The most frequent region of chromosomal loss was
between 3p2l.3-22.1 (overall LOH 33%), with a separate
area of deletion at 3pl2.1-13 (overall LOH 14.8%). LOH at
3p24-pter, which has been previously reported for head andAllelic deletions in oral dysplasia
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Table II Polymorphic markers used and LOH at each locus
Allelic loss/informative cases
Dysplasia only Dysplasia
Locus Map position (%) with SCC (%) All cases (%)
D3S1307 3p26.5 1/12 (0) 1/12 (8.3) 1/24 (4.1)
D3S1038 3p26.2 -25.3 0/12 (0) 1/1 1 (9) 1/23 (4.3)
D3S192 3p26.1 -24.2 0/15 (0) 1/10 (10) 1/25 (4.0)
D3S1007 3p26.1 -25.1 1/16 (6.3) 0/13 (0) 1/29 (3.4)
D3S1293 3p24.3 0/11 (0) 0/9 (0) 0/20 (0)
D3S647 3p24.1-22.1 0/12 (0) 0/11 (0) 0/23 (0)
D3S32 3p22.1-21.2 3/14 (21.4) 1/12 (8.3) 4/26 (15.4)
D3S686 3p21.3 2/10 (20) 2/11 (11.1) 4/21 (19.0)
D3S966 3p21.32-21.31 2/12 (16.7) 1/9 (11/1) 3/21 (14.3)
D3S1076 3p2.1 -14.2 0/9 (0) 0/9 (0) 0/18 (0)
D3S1228 3p14.2 - 14.1 0/14 (0) 1/11 (9) 1/25 (4.0)
D3S1079 3pl3 0/7 (0) 0/6 (0) 0/13 (0)
D3S659 3p13 1/12 (4.7) 0/9 (0) 1/21 (4.7)
D3S30 3pl2.3-12.1 2/13 (15.3) 1/8 (12.5) 3/21 (14.3)
D3S196 3q27-28 1/12 (8.3) 0/5 (0) 1/17 (5.8)
D3S1209 3q21 -24 0/13 (0) 0/8 (0) 0/21 (0)
TP53 17p13.1 3/16 (18) 2/10 (20) 5/26 (19.2)
DCC 18q21.3 1/11 (9) 4/9 (44.4) 5/21 (23.8)
a
Iq
- "
- In
- In
CD CD L LO' O N N - -:-- w (N (N
(N(N(N(N (NCN ( NN NCNN N (N ;; (N(N !
{11111111111l
D3S1307 D3S1293 D3S32 D3S1079
D3S1038 D3S686 D3S1228 D3S30
D3S1007 D3S647 D3S966 D3S659
D3S192 D3S1076
Poterntially
b malignant lesions
D3S196 r3 N N I N M
TP53 J1I II
DCC
Irnvasive SCC
-mI I I l
* LOH M Uniformative Retained
Figure 1 (a) Map position of the markers as indicated by the
Sigma mapping programme using data from the Genome Data
Base. (b) Deletion map of chromosomal regions in potentially
malignant oral lesions and invasive SCC with partial 3p loss and
LOH at TP53 and DCC. Dysplastic lesions that retained
heterozygosity at the loci examined are not shown. The case
numbers are at the top. The markers used are shown on the left.
The order of the markers is given as suggested by their map
position and the pattern of allelic deletions in the tumours
examined. *, LOH; 0, uninformative; 0, retained.
.ieck and oral cancer (Masetro et al., 1993; Naggar et al.,
1993; Partridge et al., 1994; Wu et al., 1994) was seen in one
vase but might be caused by random events. The overall
.requency of allele loss for loci at 3q was <6%. Ten of the
Loci examined at 3p also showed LOH between 0% and 5%,
strongly suggesting that random loss in these lesions is a rare
event and that allelic deletions at TP53, DCC, 3p21.3-22.1
and 3pl2.1-13 are specific for potentially malignant oral
lesions.
When all loci examined are considered, 9 of 17 dysplastic
lesions without SCC and 7 of 13 cases associated with SCC
showed allele imbalance at TP53, DCC, 3p2l.3-22.1 and
3pl2.1-13 an overall LOH of 53% and 54% respectively.
Thirteen of these 16 cases occurred in smokers or patients
who regularly chewed betel quid, including tobacco. Allele
imbalance was also detected in the young adults screened
(cases 15 and 16) suggesting that this can be an early event
when recognised risk factors are present. High alcohol intake
is another recognised risk factor for oral cancer. However in
this series heavy drinkers were also heavy smokers so the
effect of alcohol alone cannot be assessed. Allele imbalance
was seen at all sites in the mouth and not restricted to the
floor of the mouth where carcinogens might be expected to
accumulate.
LOH or allele imbalance at specific chromosomal regions
was not associated with the grade of the dysplasia. These
abnormalities were detected in mild (five) moderate (two) and
severe dysplasia (two) in the absence of SCC and also in mild
(two), moderate (three) and severe (two) cases with an
invasive component. Normal oral mucosa was analysed for
16 cases with allele imbalance (7,9,15-17,20-30) and
retained all alleles tested. During the period of study 11
patients developed new dysplastic lesions at the same site (see
Table I), seven of these cases (2,7,13,15-17,28) showed LOH
or allelic imbalance at the regions identified in the original
biopsy.
Two cases (13 and 17) subsequently developed SCC at the
site of the original dysplastic lesion. Both precancers showed
LOH or allelic imbalance at 3p2l.3-22.1 and 3pl2.1-13 in
the original biopsy, case 13 showed an additional deletion at
TP53 in the paired tumour although D3S659 was retained.
Nine of the SCCs that developed adjacent to the dysplastic
lesions examined were also available for study (cases 22-30).
All tumours showed LOH or allele imbalance at TP53, DCC
or the three regions identified at 3p, 3p24-pter, 3p2l.3-22.1
and 3pl2.1-13 (Figure 1). Loss of several adjacent loci was
frequently detected in the SCC that developed (24,25,27,28).
One (five cases), two (three cases) or three (two cases) further
regions of deletion were detected when the tumours were
compared to the paired dysplastic lesions (Figure 1). Two
cases showed allele loss at D3S659 (3pl3, case 13) and DCC
(case 24, see Figure 2) in the dysplasia but not in the tumour.
Cases 13 and 24 contained >90% malignant cells suggesting
that this finding may be a reflection of 'field change' within
the oral mucosa.Allelic deletions in oral dysplasia
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Figure 2 Examples of LOH and allele imbalance at D3S192 (case 27), D3S686 (18,7), D3S32 (9,15,17), D3S30 (28,16,17), TP53
(23,24) and DCC (24,25,26) in potentially malignant oral lesions. Cases 25 and 26 retain heterozygosity at D3S192, case 24 shows
LOH at DCC in the dysplasia but not in the tumour (T), case 26 shows LOH at DCC in the dysplasia and tumour. Markers were
amplified from DNA derived from normal mucosa (N) cases 1-11, venous blood (N) cases 12-30, dysplasia (D) and tumour (T).
The case numbers are indicated above each panel. The numbering of the patients is the same as used in Table I. ai and aii represent
the polymorphic alleles, size markers (M)l kb ladder.
Discussion
At present, assessment of the likely behaviour of pre-
cancerous lesions relies on examination of sections stained
with haematoxylin and eosin. There is general agreement that
the degree of atypia and other structural alterations can be
classified as mild, moderate or severe and this is normally
taken to indicate low, medium or high risk of progression to
malignancy (Maerjer and Burkardt, 1976). However this type
of analysis is likely to be unreliable as a result of the subject-
ivity inherent in this kind of assessment and the different
histological criteria used to define dysplasia in different cen-
tres. The carcinogenic process involves progressive accumula-
tion of genetic abnormalities (Fearon and Vogelstein, 1990)
and assessment of the number of 'hits' in oral precancer by
regular molecular profiling from biopsy tissue might supple-
ment histological assessment to help identify lesions which
may recur or progress to malignancy.
This report is the first to describe allelic loss or imbalance
at TP53, DCC and regions at 3p in potentially malignant
lesions but not in histologically normal oral mucosa. These
genetic abnormalities were detected in mild, moderate and
severe dysplasia, which suggests that tumour-suppressor
genes may be inactivated at an early stage in the carcinogenic
process. At least two regions of deletion at 3p were identified
at 3p21.3-22.1 and 3pl2.1-13, areas that have previously
been suggested to harbour potential tumour-suppressor genes
for head and neck and oral cancer (Masetro et al., 1993;
El-Naggar et al., 1993; Partridge et al., 1994; Wu et al.,
1994). LOH at 3p24-pter, was also seen in one case but
might be due to random events. The majority of cases of
LOH at DCC occurred in dysplastic lesions adjacent to frank
SCC, suggesting that loss at this locus may be a later event.
Preliminary studies have also shown that deletion of DCC is
a common event in oral cancer (data not shown).
In this study it was revealed that 13 of 16 patients with
allelic imbalance at the chromosomal regions studied were
smokers, suggesting that these areas may be some of the sites
of genetic damage in this group of patients. This reinforces
the view that individuals with potentially malignant oral
lesions should be encouraged to stop smoking.
The same allele was lost in the dysplastic oral epithelium
and five of seven paired tumours, favouring a monoclonal
origin for most samples examined. Two cases showed
different deletions in the dysplastic and malignant lesion
suggesting a polyclonal process and revealing a molecular
basis for 'field cancerisation' within the oral cavity (Slaughter
et al., 1953). This finding contrasts with a study of tumours
of the larynx and hypopharynx (Nees et al., 1993) showing
different TP53 mutations in all cases of tumour and tumour-
distant mucosa examined, suggesting a multifocal polyclonal
process within the upper aerodigestive tract.
LOH or allele imbalance at the regions studied occurred in
7 of 11 (64%) dysplastic lesions that recurred within 3 years.
Deletion of loci at 3p2l.3-22.1, 3pl2.1-13 and TP53 was
most frequent in these samples and may be related to altered
cell proliferation within the epithelia. The number of allelic
deletions or 'hits' was higher in the tumours adjacent to the
dysplastic lesions and in the tumours that subsequently
developed. As these specific deletions can be present in
potentially malignant lesions and increase in number when
SCC develops they may serve as a marker to identify lesions
that may recur or progress to cancer. Long-term study of
sequential biopsies of dysplastic and tumour samples
obtained from a large series of patients is in progress to
determine whether the frequency of allele loss in dysplastic
lesions can predict the likely behaviour of these lesions. If an
accumulation of these genetic abnormalities is shown to inc-
rease risk of tumour development this would help identify
individuals who may benefit from regular oral screening
examination and early intervention.
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